KraneShares MSCI All China Health Care Index ETF in 1 story
The narratives KURE currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
KURE in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
KURE provides diversified exposure to Chinese biotechnology, pharmaceutical, hospital and healthcare companies that could benefit from rising global demand for China-origin drug assets.
Bear side
0 storiesNo bear-side stories for KURE yet.